Pricing and reimbursement of CAR‐T in Germany

CAR-T therapy: the future begins to take shape

High expectations have been built up around the pricing, reimbursement, and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies based on the novel mechanism of action and trial results that indicate curative potential for a large segment of the treatable population. However, CAR-T represents an entirely new way of delivering cancer therapy, with significant challenges for manufacturers and healthcare systems.

This eBook provides:

  • overviews of pricing and reimbursement of CAR‐T in France, Germany, and the UK
  • a summary of five key issues that are emerging from early regulatory, pricing, and reimbursement decisions
  • five strategies for success that manufacturers could consider.

FREE EBOOK

Free download

Latest insights

Recommendations for driving your journey to digital ...

Five ways to break down the silos ...

How one colleague’s fundraising at home ...